News Archives - Livin Well Life https://livinwellife.com/category/news/ Find Latest Articles on E-Business, Affiliate Guides, Health, Fitness, Home & Garden, Business and Investing etc. Tue, 29 Nov 2022 00:34:32 +0000 en-US hourly 1 https://wordpress.org/?v=6.1.1 https://livinwellife.com/wp-content/uploads/2021/09/cropped-livinwellfav1-32x32.png News Archives - Livin Well Life https://livinwellife.com/category/news/ 32 32 Cerebral sues former CEO over alleged unpaid loan https://livinwellife.com/cerebral-sues-former-ceo-over-alleged-unpaid-loan/ https://livinwellife.com/cerebral-sues-former-ceo-over-alleged-unpaid-loan/#respond Tue, 29 Nov 2022 00:34:32 +0000 https://livinwellife.com/cerebral-sues-former-ceo-over-alleged-unpaid-loan/ Cerebral sues former CEO over alleged unpaid loan

Cerebral is suing its ousted cofounder Kyle Robertson, alleging he never repaid a loan received from the digital mental health company.  According to a lawsuit filed last week in New York, Cerebral said Robertson defaulted on a nearly $50 million loan that he took out in January to buy 1.06 million shares of common stock […]

The post Cerebral sues former CEO over alleged unpaid loan appeared first on Livin Well Life.

]]>
Cerebral sues former CEO over alleged unpaid loan



Cerebral is suing its ousted cofounder Kyle Robertson, alleging he never repaid a loan received from the digital mental health company. 

According to a lawsuit filed last week in New York, Cerebral said Robertson defaulted on a nearly $50 million loan that he took out in January to buy 1.06 million shares of common stock in the company. Cerebral alleges Robertson is personally liable for more than half of the loan amount plus interest and attorney’s fees. 

The suit said the cofounder of the digital mental health startup had the option to pay in cash or direct Cerebral to repurchase or cancel the pledged shares. Cerebral alleges Robertson “repeatedly asserted that he would not repay the loan despite his obligation to do so under the note within six months of his termination.”

Robertson was replaced as CEO of the company in May as Cerebral faced growing controversy over its prescribing practices, particularly for controlled substances like Adderall. He didn’t immediately respond to a request for comment from Bloomberg about the lawsuit. 

THE LARGER TREND

The embattled mental health company scooped up huge numbers of investor dollars last year, including a $300 million raise announced in December 2021. In April, a former Cerebral executive sued the company, alleging he was fired after he spoke up about unethical prescribing practices. Cerebral said it believed the complaints were “without merit.”

In May, the company confirmed it had received a grand jury subpoena from the U.S. Attorney’s Office for the Eastern District of New York over possible controlled substance violations. The Wall Street Journal has also reported Cerebral is under investigation by the Federal Trade Commission. The company has said it stopped prescribing most controlled substances.

Earlier this month, Insider reported on a leaked letter from Robertson, arguing Cerebral unfairly placed blame on him for the company’s prescription policies and that he faced homophobic remarks from Cerebral executives and board directors. The letter requested internal documents and records, which could be a sign of a possible upcoming lawsuit. 



Source link

The post Cerebral sues former CEO over alleged unpaid loan appeared first on Livin Well Life.

]]>
https://livinwellife.com/cerebral-sues-former-ceo-over-alleged-unpaid-loan/feed/ 0
The rising role of smart technologies in chronic disease management https://livinwellife.com/the-rising-role-of-smart-technologies-in-chronic-disease-management/ https://livinwellife.com/the-rising-role-of-smart-technologies-in-chronic-disease-management/#respond Mon, 28 Nov 2022 16:33:58 +0000 https://livinwellife.com/the-rising-role-of-smart-technologies-in-chronic-disease-management/ The rising role of smart technologies in chronic disease management

Atrial Fibrillation (AFib) is the most common heart rhythm disorder, affecting more than 40 million people worldwide.  The condition poses a five-fold increased risk of stroke, yet is often difficult to detect.  Until now, studies have shown the potential of smart devices for large-scale AFib screening but have made no comparison with conventional screening. However […]

The post The rising role of smart technologies in chronic disease management appeared first on Livin Well Life.

]]>
The rising role of smart technologies in chronic disease management



Atrial Fibrillation (AFib) is the most common heart rhythm disorder, affecting more than 40 million people worldwide. 

The condition poses a five-fold increased risk of stroke, yet is often difficult to detect. 

Until now, studies have shown the potential of smart devices for large-scale AFib screening but have made no comparison with conventional screening.

However new research presented at the European Society of Cardiology (ESC) Congress 2022, found that AFib screening using conventional smartphones more than doubles the detection and treatment rate in older people, compared to routine screening.

Increased detection rate 

The eBRAVE-AF trial, a study in 5,551 older adults at risk of stroke, saw participants randomly assigned to a six-month digital or conventional AFib screening strategy. 

Those taking part in the digital screening, downloaded an app to their smartphones that measured pulse wave irregularities using the phone’s photoplethysmographic (PPG) sensor. 

Professor Axel Bauer of Innsbruck Medical University, Austria, outlined details of the study at the ESC Congress, which took place in Barcelona during August this year. 

He explained that digital screening was well-received by older participants, who tended to perform more PPG measurements than younger participants in the study. 

“Screening using common smartphones significantly increased the detection rate of therapy-relevant atrial fibrillation,” concluded Prof Bauer.

A shift in focus 

Across the healthcare sector, technological and product advances are supporting patient diagnosis and care, with data harvested via remote monitoring being used to build clearer pictures of health conditions and improve patient experience. 

There has also been an increasing shift in focus from electrocardiogram (ECG) based signals towards the type of PPG-based bio-signals common to wearable devices.

One example is US digital healthcare firm iRhythm Technologies, which recently received FDA 510(k) clearance for its Zio ECG Utilization Software (ZEUS) System, which works with a wearable to monitor AFib patients. 

Tech giants Apple and Fitbit have also entered the AFib detection and tracking space, while South Korean firm Sky Labs has an established CART-I smart ring, which helps detect AFib in patients.

Better signal quality 

The CART-I smart wearable heart rhythm monitoring device utilises PPG signals to measure heart rate from screening the bloodstream 24/7. Long-term changes can be picked up and relayed back to the physician by the CART-I smart ring. 

“With CART-I, the patient can collect their own data and easily transfer that real-time continuous data to the doctor,” explained Sky Labs CEO Jack Lee.

Studies have acknowledged that the finger provides greater sensitivity for sensors, with more accurate and better signal quality, because it has a higher volume of atrial blood flow than other parts of the body.

The CART-I’s evolution is set to continue next year with the release of a new smart ring feature that will measure blood pressure without any user intervention.

“It will offer continuous blood pressure measurement, even when a person is asleep and not aware of the device operation,” explained Lee. “By helping managing hypertension, we can prevent stroke.”



Source link

The post The rising role of smart technologies in chronic disease management appeared first on Livin Well Life.

]]>
https://livinwellife.com/the-rising-role-of-smart-technologies-in-chronic-disease-management/feed/ 0
Lunit supercharges global expansion with latest market approvals, major distribution deal https://livinwellife.com/lunit-supercharges-global-expansion-with-latest-market-approvals-major-distribution-deal/ https://livinwellife.com/lunit-supercharges-global-expansion-with-latest-market-approvals-major-distribution-deal/#respond Mon, 28 Nov 2022 08:32:38 +0000 https://livinwellife.com/lunit-supercharges-global-expansion-with-latest-market-approvals-major-distribution-deal/ Lunit supercharges global expansion with latest market approvals, major distribution deal

South Korean medical AI company Lunit is further cementing its global presence after securing a new international distribution deal and major market approvals.  Last week, it announced that Lunit INSIGHT CXR and MMG have been given the UK Conformity Assessed marking and CE marking under the latest Medical Device Regulation in Europe.  The company claims it has […]

The post Lunit supercharges global expansion with latest market approvals, major distribution deal appeared first on Livin Well Life.

]]>
Lunit supercharges global expansion with latest market approvals, major distribution deal



South Korean medical AI company Lunit is further cementing its global presence after securing a new international distribution deal and major market approvals. 

Last week, it announced that Lunit INSIGHT CXR and MMG have been given the UK Conformity Assessed marking and CE marking under the latest Medical Device Regulation in Europe. 

The company claims it has become the first software as medical device developer in Asia-Pacific to have received both certifications, which follows its recent clearances obtained from Taiwan and Canada.

Also last week, Lunit signed a global distribution agreement with California-based healthcare platform CARPL.ai. Under this deal, the two popular Lunit INSIGHT solutions, INSIGHT CXR for chest x-ray image analysis and INSIGHT MMG for mammography analysis, will be delivered through CARPL.ai’s end-to-end deployment platform, which currently runs across five markets: the United States, Australia, Brazil, India, and Singapore.

Lunit INSIGHT solutions are already embedded in some major global PACS and imaging devices by global vendors such as GE Healthcare, Philips, and Fujifilm. Both Lunit INSIGHT CXR and MMG are now being clinically used in approximately 1,000 hospitals and medical institutions worldwide.

MARKET SNAPSHOT

In recent years, South Korean AI imaging companies like Lunit have been securing local and international approvals and deals to meet the growing demand from hospitals. 

One of the major players, Vuno, has recently obtained the South Korean government’s approvals for its personal ECG devices, Hativ Pro and Hativ P30. Outside the country, it also gained accreditations from Taiwan for its AI bone age analysis software and from Singapore for its AI fundus analysis software.

Another company, AITRICS, received South Korea’s nod for its AI patient monitoring solution while JLK secured Thailand’s clearance for its AI brain image analysis solution. Coreline Soft has also recently obtained the US Food and Drug Administration’s 510(k) certification for AVIEW RT ACS, its AI-based automatic organ contouring solution.

Meanwhile, Lunit has become one of the preferred suppliers of AI imaging solutions for South Korean military hospitals as part of the Armed Forces Medical System AI Transformation project. It is set to deliver its technology across 30 medical sites of the Korean army, air force and navy. Internationally, its AI solutions have been recently adopted by Cathay Life Insurance in Taiwan, Thailand’s Bumrungrad International Hospital, Egypt-based non-profit Baheya Foundation, and most recently, SEHA, the largest healthcare network in the United Arab Emirates, and BreastScreen NSW in Australia. 

According to Statista, the South Korean diagnostic imaging market is expected to reach $1.02 billion in market volume by 2027, growing at a 6% CAGR from 2022.



Source link

The post Lunit supercharges global expansion with latest market approvals, major distribution deal appeared first on Livin Well Life.

]]>
https://livinwellife.com/lunit-supercharges-global-expansion-with-latest-market-approvals-major-distribution-deal/feed/ 0
10,500 Toddler Bottles and Cups Recalled Over Lead Poisoning Risk https://livinwellife.com/10500-toddler-bottles-and-cups-recalled-over-lead-poisoning-risk/ https://livinwellife.com/10500-toddler-bottles-and-cups-recalled-over-lead-poisoning-risk/#respond Mon, 28 Nov 2022 00:31:58 +0000 https://livinwellife.com/10500-toddler-bottles-and-cups-recalled-over-lead-poisoning-risk/ 10,500 Toddler Bottles and Cups Recalled Over Lead Poisoning Risk

A company has recalled about 10,500 bottles and cups for toddlers over lead poisoning concerns to children if a part of the product breaks off, the U.S. Consumer Product Safety Commission said. The base of these bottles and cups, manufactured by Green Sprouts, can come off and expose a solder dot that contains lead, posing […]

The post 10,500 Toddler Bottles and Cups Recalled Over Lead Poisoning Risk appeared first on Livin Well Life.

]]>
10,500 Toddler Bottles and Cups Recalled Over Lead Poisoning Risk


A company has recalled about 10,500 bottles and cups for toddlers over lead poisoning concerns to children if a part of the product breaks off, the U.S. Consumer Product Safety Commission said.

The base of these bottles and cups, manufactured by Green Sprouts, can come off and expose a solder dot that contains lead, posing a potential poison hazard to children, the commission said in a post dated Wednesday.

No injuries have been reported, the commission said, but the company is aware of seven incidents in which the base broke.

“Lead is toxic if ingested by young children, and can cause adverse health effects,” the commission said.

Consumers should take the bottles and cups away from children immediately and discard them, the commission said.

In a statement on its website, Green Sprouts said: “There is negligible risk to the health and safety of users. We are undertaking the costs and challenges of this recall voluntarily because our customers’ health and safety must come first.”

The solder dot, which contains lead, is supposed to be inaccessible under normal use, so this portion was not tested by a safety lab, the company said.

“As we approach the redesign of these products, whose benefits for keeping drinks cold safely have made them a popular choice for parents, we will ensure that lead is not used as a soldering material, no matter whether it would be accessible,” Green Sprouts said.

The plant-plastic and silicone lid and spout can be reused with other Green Sprouts cups and bottles, the company said.

The recalled products, which were sold in aqua, green, navy and pink, come in 6- and 8-ounce sizes. They were available at Buy Buy Baby and Whole Foods stores, and online at Amazon, Buy Buy Baby and Bed Bath & Beyond from January 2020 through September 2022, the commission said.

The commission said Green Sprouts is “contacting all known purchasers directly.” Those who bought the products can contact the company for refunds.

High levels of lead exposure in children can cause comas, convulsions and even death, according to the World Health Organization. Neurological and behavioral effects are believed to be irreversible.

“Children who survive severe lead poisoning may be left with intellectual disability and behavioral disorders,” a W.H.O. statement said.



Source link

The post 10,500 Toddler Bottles and Cups Recalled Over Lead Poisoning Risk appeared first on Livin Well Life.

]]>
https://livinwellife.com/10500-toddler-bottles-and-cups-recalled-over-lead-poisoning-risk/feed/ 0
AEYE Health receives FDA 510(k) for AI-backed diabetic retinopathy screening https://livinwellife.com/aeye-health-receives-fda-510k-for-ai-backed-diabetic-retinopathy-screening/ https://livinwellife.com/aeye-health-receives-fda-510k-for-ai-backed-diabetic-retinopathy-screening/#respond Sun, 27 Nov 2022 08:29:18 +0000 https://livinwellife.com/aeye-health-receives-fda-510k-for-ai-backed-diabetic-retinopathy-screening/ AEYE Health receives FDA 510(k) for AI-backed diabetic retinopathy screening

Israeli startup AEYE Health announced last week it had received FDA 510(k) clearance for its AI-based screening tool for diabetic retinopathy. The AEYE-DS system, which received the agency’s green light earlier this month, uses images from each eye to detect signs of more-than-mild diabetic retinopathy, a complication from diabetes that can lead to blindness or other […]

The post AEYE Health receives FDA 510(k) for AI-backed diabetic retinopathy screening appeared first on Livin Well Life.

]]>
AEYE Health receives FDA 510(k) for AI-backed diabetic retinopathy screening



Israeli startup AEYE Health announced last week it had received FDA 510(k) clearance for its AI-based screening tool for diabetic retinopathy.

The AEYE-DS system, which received the agency’s green light earlier this month, uses images from each eye to detect signs of more-than-mild diabetic retinopathy, a complication from diabetes that can lead to blindness or other serious vision problems. 

It’s currently cleared to use images obtained by the desktop retinal camera Topcon NW-400. AEYE said it was working to receive clearance to use the system with a portable camera, and that it’s studying use for screening glaucomatous optic neuropathy.

“The time has finally come for autonomous screening technology to exceed the efficacy of the human expert,” AEYE board member Dr. Sean Ianchulev said in a statement. “The implications are that it can be practical for deployment on the front lines of population health – the primary care offices, where over 99% imageability and single image diagnostic acquisition are tantamount to market success.”

THE LARGER TREND

Digital Diagnostics, formerly known as IDx, received FDA De Novo clearance in 2018 for its autonomous software for detecting diabetic retinopathy in adults. The company also expanded into dermatology with the acquisition of 3Derm about two years ago. 

Earlier this year, Digital Diagnostics raised $75 million in Series B funding to advance its product roadmap, expand distribution and invest in sales and marketing.

Another company focused on AI-backed detection of diabetic retinopathy, Eyenuk, announced it had raised $25 million in a Series A round in October. Eyenuk’s software received an FDA 510(k) in 2020.

Google has also been researching using AI for eye screenings with its Automated Retinal Disease Assessment tool. In the spring, the tech giant said it was studying whether a basic smartphone photo of the outside of the eye could detect disorders, so users could conduct assessments at home.



Source link

The post AEYE Health receives FDA 510(k) for AI-backed diabetic retinopathy screening appeared first on Livin Well Life.

]]>
https://livinwellife.com/aeye-health-receives-fda-510k-for-ai-backed-diabetic-retinopathy-screening/feed/ 0
Deforestation Brings Bat-Borne Virus Home to Roost https://livinwellife.com/deforestation-brings-bat-borne-virus-home-to-roost/ https://livinwellife.com/deforestation-brings-bat-borne-virus-home-to-roost/#respond Sun, 27 Nov 2022 00:28:26 +0000 https://livinwellife.com/deforestation-brings-bat-borne-virus-home-to-roost/ Deforestation Brings Bat-Borne Virus Home to Roost

Habitat loss and food shortages have pushed bats into closer proximity to horses and humans, fueling Hendra virus spillover, a new study suggests. Source link

The post Deforestation Brings Bat-Borne Virus Home to Roost appeared first on Livin Well Life.

]]>
Deforestation Brings Bat-Borne Virus Home to Roost



Habitat loss and food shortages have pushed bats into closer proximity to horses and humans, fueling Hendra virus spillover, a new study suggests.



Source link

The post Deforestation Brings Bat-Borne Virus Home to Roost appeared first on Livin Well Life.

]]>
https://livinwellife.com/deforestation-brings-bat-borne-virus-home-to-roost/feed/ 0
FDA Approves a Drug That Can Delay Type 1 Diabetes https://livinwellife.com/fda-approves-a-drug-that-can-delay-type-1-diabetes/ https://livinwellife.com/fda-approves-a-drug-that-can-delay-type-1-diabetes/#respond Sat, 26 Nov 2022 16:26:40 +0000 https://livinwellife.com/fda-approves-a-drug-that-can-delay-type-1-diabetes/ FDA Approves a Drug That Can Delay Type 1 Diabetes

Now that the drug is approved, the challenge will be to find people who could benefit. Screening only people with immediate relatives who have diabetes will miss 85 percent of patients. The JDRF, a nonprofit group that advocates for people with Type 1 diabetes and supports research, which, along with the N.I.H., funded the trial […]

The post FDA Approves a Drug That Can Delay Type 1 Diabetes appeared first on Livin Well Life.

]]>
FDA Approves a Drug That Can Delay Type 1 Diabetes


Now that the drug is approved, the challenge will be to find people who could benefit. Screening only people with immediate relatives who have diabetes will miss 85 percent of patients.

The JDRF, a nonprofit group that advocates for people with Type 1 diabetes and supports research, which, along with the N.I.H., funded the trial that led to the drug’s approval, wants antibody screening tests to become part of routine pediatric care.

“Most families say diagnosis is a bolt out of the blue,” said Aaron Kowalski, chief executive of the JDRF. And most patients, he added, are very sick when they first are diagnosed.

The group has conducted blood tests to look for antibodies in Germany and in parts of Colorado. And it has offered an at-home test people can order, underwritten by the foundation. But, Dr. Kowalski said, “we want pediatric offices to do it.”

Testing also offers another opportunity, he said. It turns out that antibodies indicating an immune attack often occur when people are as young as 5 or 6 years old, although most do not develop diabetes until they are teenagers.

Now, he said, his hope is to treat people even earlier, as soon as those antibodies emerge. Clinicians and the F.D.A. had previously objected to treating before the disease was clearly underway, asking, “How can you give an immunotherapy if they are normal?” Dr. Kowalski said.

But, he said, the antibodies tell a different story.

“They do have diabetes,” he said, although not according to the usual definition of the disease. “It just hasn’t unmasked itself yet. We need to help them save their beta cells,” the insulin-secreting cells of the pancreas.



Source link

The post FDA Approves a Drug That Can Delay Type 1 Diabetes appeared first on Livin Well Life.

]]>
https://livinwellife.com/fda-approves-a-drug-that-can-delay-type-1-diabetes/feed/ 0
Healthcare fintech PayZen raises $20M, receives $200M credit facility https://livinwellife.com/healthcare-fintech-payzen-raises-20m-receives-200m-credit-facility/ https://livinwellife.com/healthcare-fintech-payzen-raises-20m-receives-200m-credit-facility/#respond Sat, 26 Nov 2022 08:25:50 +0000 https://livinwellife.com/healthcare-fintech-payzen-raises-20m-receives-200m-credit-facility/ Healthcare fintech PayZen raises $20M, receives $200M credit facility

Healthcare fintech PayZen raised $20 million in an equity funding round, led by 7wireVentures, and received a $200 million credit facility from Viola Credit. Others participating in the equity raise include previous investors SignalFire, Link Ventures and Picus Capital. Lee Shapiro, managing partner at 7wireVentures and former chief financial officer of chronic care management company […]

The post Healthcare fintech PayZen raises $20M, receives $200M credit facility appeared first on Livin Well Life.

]]>
Healthcare fintech PayZen raises $20M, receives $200M credit facility



Healthcare fintech PayZen raised $20 million in an equity funding round, led by 7wireVentures, and received a $200 million credit facility from Viola Credit.

Others participating in the equity raise include previous investors SignalFire, Link Ventures and Picus Capital. Lee Shapiro, managing partner at 7wireVentures and former chief financial officer of chronic care management company Livongo, will join PayZen’s board. 

The startup announced it had raised $15 million in Series A funding about a year ago, following a more than $5 million seed round in early 2021.

WHAT IT DOES

Founded in 2019, PayZen touts a “care now, pay later” model for healthcare. The startup pays providers for patients’ invoices and then uses artificial intelligence to create individualized repayment plans lasting up to 60 months with no interest or fees. 

The startup partners with health systems to integrate its platform into providers’ revenue cycle management systems. Last year, it announced it was working with Danville, Pennsylvania-based Geisinger.

PayZen also offers a debit card that patients can use before they receive healthcare services, like for recurring appointments for chronic conditions or pharmacy spending. It plans to use the capital to scale operations and product development. 

“This exciting round is a testament to PayZen’s product innovation and the immense need for more affordable payment options for patients who are trying to pay their medical bills,” PayZen cofounder and CEO Itzik Cohen said in a statement. “Healthcare equity and affordability is a foundational problem in the U.S. Too many Americans have delayed or foregone getting the care they need because they aren’t offered an affordable way to pay. At PayZen, we’re determined to help fix this broken system.”

MARKET SNAPSHOT

Healthcare affordability is a major concern in the U.S. According to a survey by the Kaiser Family Foundation, nearly half of U.S. adults say it is very or somewhat difficult for them to afford their healthcare, and one third said they or a member of their household has delayed care due to cost.

A recent Gallup poll found three quarters of respondents gave healthcare affordability in the U.S. a failing grade.

Other health tech companies focused on payment include Cedar, which raised $200 million last year but recently laid off 24% of its workforce; Inbox Health, which scooped up $15 million in Series A funding in 2021; and Cherry Technologies, which received a $50 million credit facility earlier this year. 



Source link

The post Healthcare fintech PayZen raises $20M, receives $200M credit facility appeared first on Livin Well Life.

]]>
https://livinwellife.com/healthcare-fintech-payzen-raises-20m-receives-200m-credit-facility/feed/ 0
Study Finds Hemp-Fed Cows Had Traces of THC in Their Milk https://livinwellife.com/study-finds-hemp-fed-cows-had-traces-of-thc-in-their-milk/ https://livinwellife.com/study-finds-hemp-fed-cows-had-traces-of-thc-in-their-milk/#respond Sat, 26 Nov 2022 00:24:15 +0000 https://livinwellife.com/study-finds-hemp-fed-cows-had-traces-of-thc-in-their-milk/ Study Finds Hemp-Fed Cows Had Traces of THC in Their Milk

Perhaps more important, at least for humans, the THC made its way into their milk, sometimes at levels that exceeded consumption limits set by food safety regulators in Europe. (The United States has no comparable standard. The Centers for Disease Control and Prevention does advise new mothers to avoid marijuana and CBD products while breastfeeding, […]

The post Study Finds Hemp-Fed Cows Had Traces of THC in Their Milk appeared first on Livin Well Life.

]]>
Study Finds Hemp-Fed Cows Had Traces of THC in Their Milk


Perhaps more important, at least for humans, the THC made its way into their milk, sometimes at levels that exceeded consumption limits set by food safety regulators in Europe. (The United States has no comparable standard. The Centers for Disease Control and Prevention does advise new mothers to avoid marijuana and CBD products while breastfeeding, saying the research on the effects of passing even trace amounts to an infant remains unclear.)

That said, THC became undetectable soon after the hemp was removed from the cows’ diet. Apparent signs of intoxication, including red-rimmed eyes, runny noses and what the study authors described as an “unsteady gait” and “abnormal posture” faded within two days after the cows went cold turkey.

Dr. Robert Pieper, a lead author of the study, said it was unclear whether the slump in milk output was caused by THC or perhaps by one or more of the dozens of other cannabinoids or chemicals found in hemp plants.

More research was needed, he said.

“Hemp is a very versatile and valuable crop, but we have to be careful when considering whether to feed it to food-producing animals,” said Dr. Pieper, who heads the food chain safety division at the German Federal Institute.

The findings are largely in sync with other recent studies conducted in the United States that involved hemp and livestock. Researchers at Oregon State University who fed hemp to sheep found small amounts of THC in the animal’s muscle and fat, but the chemical vanished several weeks after the hemp was removed from their diet. Serkan Ates, an associate professor at Oregon State’s College of Agricultural Sciences, said the studies he and his colleagues had done with sheep and dairy cows had convinced him that there are few downsides to introducing hemp into the diets of farm animals, especially given the soaring cost of conventional feed. “The nutritional value of hemp is really high but most of it is ending up in landfill or being composted,” he said.

In studies done at Kansas State University, THC showed up in the plasma of hemp-fed cattle, but researchers there also discovered something unexpected: The animals were notably more relaxed, according to biomarkers that indicate stress levels. As in the German study, which recorded lower heart and respiratory rates in cows that consumed high levels of THC, the animals also spent more time lying down alongside their barn mates.



Source link

The post Study Finds Hemp-Fed Cows Had Traces of THC in Their Milk appeared first on Livin Well Life.

]]>
https://livinwellife.com/study-finds-hemp-fed-cows-had-traces-of-thc-in-their-milk/feed/ 0
Roundup: Indian startups score new fundings and more briefs https://livinwellife.com/roundup-indian-startups-score-new-fundings-and-more-briefs/ https://livinwellife.com/roundup-indian-startups-score-new-fundings-and-more-briefs/#respond Fri, 25 Nov 2022 16:22:59 +0000 https://livinwellife.com/roundup-indian-startups-score-new-fundings-and-more-briefs/ Roundup: Indian startups score new fundings and more briefs

Ayurveda tech startup NirogStreet snaps up $12M in Series B funding NirogStreet, an Ayurveda technology platform in India, has scored $12 million in a Series B funding round led by Jungle Ventures. It provides a community for Ayurveda doctors and an e-commerce platform that streamlines the supply chain of Ayurvedic services and medicine. NirogStreet has onboarded around 50,000 […]

The post Roundup: Indian startups score new fundings and more briefs appeared first on Livin Well Life.

]]>
Roundup: Indian startups score new fundings and more briefs



Ayurveda tech startup NirogStreet snaps up $12M in Series B funding

NirogStreet, an Ayurveda technology platform in India, has scored $12 million in a Series B funding round led by Jungle Ventures.

It provides a community for Ayurveda doctors and an e-commerce platform that streamlines the supply chain of Ayurvedic services and medicine. NirogStreet has onboarded around 50,000 medical practitioners and about 50 Ayurveda brands.

The startup will use the proceeds from its latest investing round to bolster its supply chain, technology, and services. 


Men’s health startup Bonatra obtains pre-seed funding

Bonatra, a men’s health-focused startup from India, has raised INR 55 million ($670,000) in a pre-seed funding round led by ITI Growth Opportunities Fund with the participation of marquee angel investors, Jitendra Jagadev, founder of Nestaway, and Blackbuck founder Rajesh Yabaji. 

The company runs a technology platform that offers personalised health programmes targeting chronic conditions of men.

In a statement, Bonatra said that its fresh funds will be used to expand its offerings, build its team, and grow its client base.


Edenlux introduces AI report to its mobile eye health app

South Korean medical device maker Edenlux is now providing AI-generated eye health management reports through its flagship mobile app Otus Plus. 

The app allows users to test their eye health with a paired goggle device, do gamified eye exercises, and receive an eye health report.

Its eye health reports now contain AI-generated eye health scores, analysis of eye focus reaction speed, and results of eye exercise games based on users’ data. 

In the future, Edenlux plans to add an improvement indicator to its reports, as well as offer a service that allows users to choose their own customised lenses for eye exercises and use accumulated data to provide an eye health score report.


Cha Vaccine ties up with MOGAM for AI drug discovery

The MOGAM Institute for Biomedical Research has signed a memorandum of understanding with the Cha Vaccine Institute for AI drug discovery.

They will cooperate to develop new drugs and improve drug substances using MOGAM’s AI algorithms, which will be tested using medical data from Cha Vaccine. Later, they will conduct joint studies and apply for co-patents.



Source link

The post Roundup: Indian startups score new fundings and more briefs appeared first on Livin Well Life.

]]>
https://livinwellife.com/roundup-indian-startups-score-new-fundings-and-more-briefs/feed/ 0